Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial.
Journal Information
Full Title: Diabetol Metab Syndr
Abbreviation: Diabetol Metab Syndr
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Endocrinology & Metabolism
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateConsent has been obtained from each patient after full explanation of the purpose and nature of all procedures used. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."
"Funding This study was funded by China Endocrine Metabolism Talent Research Fund (no. 2022-N-02-07), Bethune Charitable Foundation (no. Z04JKM2022E035), the Scientific Research Funding of Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin Key Laboratory of Metabolic Diseases (no. ZXY-ZDSYS2020-4 and ZXY-ZDSYSZD2022-1), the Project of Science and Technology Popularization Activity in Tianjin (22KPHDRC00060), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-032A), and the Nature Science Foundation of Tianjin, China (no. 21JCQNJC00460)."
"Trial Registration: Chu Hsien-I Memorial Hospital of Tianjin Medical University (ChiCTR2000037951)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025